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Cancer is a leading cause of death in both developing 
and less developed countries (Torre et al., 2015). 
Globally, colorectal cancer (CRC) is the third mostly 
diagnosed type of cancer amongst males, and the 
second in females (Torre et al., 2015). In Gaza 
however, colon cancer is the second mostly 
diagnosed type of cancer representing 10% of 
cancer cases, the first mostly diagnosed in males, the 
second mostly diagnosed in females (Bitar, 2015). 
The high incidence rate of CRC is attributed to a 
number of factors, including unhealthy lifestyle, 
growth, and aging of the population (Torre et al., 
2015). The impact of the disease extends to affect 
the economic, social, psychological aspects of the 
quality of life in cancer patients. 
A crucial step to reduce CRC mortality is the 
detection of early-stage cancer and precancerous 
lesions (Huang et al., 2010). Several tests or 
procedures are used for the early detection of CRC 
including fecal occult blood test, flexible 
sigmoidoscopy, double contrast barium enema, and 
colonoscopy (Smith, Cokkinides, & Eyre, 2006). 
However, because of their low adherence rates, high 
cost or low sensitivity, none of these methods is 
regarded as a well-accepted screening tool (Huang 
et al., 2010). Despite the improvements in these 
screening methods, only 30% to 40% of CRC 
patients are diagnosed at an early stage. For a 
screening method to be considered ideal, it should 
have a high sensitivity and specificity for early-stage 
CRC and precancerous lesions. In addition, this 
method should be safe and affordable so that it can 
be broadly accepted by patients and oncologists 
(Huang et al., 2010). Thus, an effective and safe early 
stage screening methods would have substantial 
clinical benefits, and would reduce the mortality of 
patients with CRC (Bo et al., 2009). 
The identification of transcription factors which play 
a key role in colorectal cancer progression is 
important because they may represent good 
diagnostic biomarkers and targets in the 
development of novel therapeutic approaches to 
treat this cancer. The rationale for this is based on 
the principle that transcription factors are 
ultimately responsible for controlling gene 
expression patterns resulting in tumor formation,
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progression and metastasis. In the last decade, several 
transcription factors with key roles in colorectal cancer 
progression were identified as potential therapeutic 
targets.  
The T-box family of transcription factors are important 
developmental regulators and have been shown to 
contribute to several human syndromes (Naiche, 
Harrelson, Kelly, & Papaioannou, 2005; Peres & Prince, 
2013). In addition to their key role in development, 
extensive investigations suggest that over expression of 
some T-box factors, including TBX2 and TBX3 may 
drive cancer (American Cancer Society, 2013; Bilican & 
Goding, 2006; Burgucu et al., 2012; Demay et al., 2007; 
Hoogaars et al., 2008; Humtsoe et al., 2012; Liu, Jiang, & 
Zhang, 2010; Peres et al., 2010; Peres & Prince, 2013). 
Both transcription factors are up-regulated in a number 
of cancers including melanoma (Hoek et al., 2004) 
breast cancer (Wu et al., 2001) and Colorectal cancer 
(Shan et al., 2015) where they were shown to be 
required for tumour formation and cell migration 
(Jacobs et al., 2000; Peres & Prince, 2013; Redmond et 
al., 2010; Yu et al., 2010). Importantly, knocking down 
TBX2 and TBX3 was shown to reverse key features of 
the melanoma and breast cancer phenotype suggesting 
that it may be a useful target in the development of 
novel anti-cancer drugs to treat these cancers (Peres et 
al., 2010; Wansleben, Davis, Peres, & Prince, 2013). 
Furthermore, silencing Tbx3 in rat bladder carcinoma 
cells rendered the cells sensitive to doxorubicin-
induced apoptosis and the overexpression of TBX3 was 
associated with a chemotherapy-resistant phenotype 
(Claire-Angélique Renard et al., 2007). Similar findings 
showed that knocking down TBX3 sensitized human 
colorectal carcinoma cells to doxorubicin via activating 
the p14- p53 pathway (Zhang et al., 2011). Taken 
together these findings suggest that TBX2 and/or TBX3 
are promising molecular markers and their depleting as 
new targets in cancers where they are over expressed 
might enhance the anti-cancer activity of 
chemotherapeutic drugs. 
The current study therefore tested the possible role of 
TBX3 in response to cisplatin chemotherapeutic 
treatment in colorectal cancer cells. Our results 
demonstrate that cisplatin treatment initially increases 
TBX3 level but Moreover, the current results show that 
knocking down tbx3 enhances cisplatin cytotoxic effect 
which might suggests anti-chemotherapeutic role of 
TBX3 in colorectal cancer. 
 
2. Material and methods:  
2.1 Cell culture:  
The human cell line HT-29 colorectal cancer cells were 
maintained in RPMI 1640 medium (Highveld Biological, 
Lynd-hurst, UK). Media were supplemented with 10% 
fetal bovine serum (FBS), 100 U/mL penicillin and 100 
µg/mL streptomycin. Cells were maintained at 37°C in a 
5% CO2 and 95% air-humidified incubator. Media was 
replaced every 2-3 days and cells were routinely 
subjected to mycoplasma tests. Only mycoplasma free 
cells were used in experiments.  
2.2 Cisplatin treatment: 
Cisplatin (CDDP) (Pfitzer, South Africa) was used as a 
positive control for melanoma treatment (Matin et al., 
2013; Mirmohammadsadegh et al., 2007). Cells were 
treated with CDDP at specific concentrations as 
indicated in each experiment. In all cases untreated 
cells were incubated with 150 mM NaCl (the vehicle in 
which CDDP was dissolved in). Cells were incubated in 
the dark at 37°C. 
2.3 Cytotoxicity assays:  
To determine the cytotoxic effect of the indicated 
compounds and drugs, cells were seeded (3000-6000 
cells/well) in quadruplicate in a 96-well plate and 
treated after two days with a range of the indicated 
concentrations of specific compounds or vehicles for 48 
hours. Cell viability was determined using the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenylte-trazolium 
bromide (MTT) assay according to the manufacturer‘s 
instructions (Roche, USA). Briefly, 10 μL of MTT 
solution was added to each well and incubated for 4 
hours at 37°C. This was followed by the addition of 100 
μL solubilisation buffer (10% SDS in 0.01 M HCl) and 
incubated overnight at 37°C. Absorbance (585 nm) was 
then determined for each well and the mean cell 
viability was calculated as a percentage of the control. 
Three separate experiments were performed to 
determine the concentration of cisplatin required to kill 
50% of the cells (IC50). The IC50 values were calculated 
from sigmoidal plots with GraphPad Prism version 5. 
2.4 Western blot analysis: 
Cells were washed twice with ice-cold PBS and 
collected by scraping with a 1 ml plunger. Whole cell 
extracts were prepared using 2X Laemmli sample 
buffer (see appendix, section 6.6), boiled for 10 min and 
stored at -20°C. Alternatively, whole cell extracts 
prepared from cells using RIPA buffer were stored on 
ice for 30 min and collected by centrifugation at 12 000 
TBX3 Role in Colorectal Cancer Treatment  Saeb Aliwaini 







IUG Journal of Natural g Studies (Islamic University of Gaza) / CC BY 4.0 
 
rpm for 20 min at 4°C. The protein concentration for 
each cell extract was determined using the BCA Protein 
Assay kit (Pierce, USA), with bovine serum albumin as 
the standard. Equal amounts of protein were loaded in 
each lane and resolved on 6-15 % SDS-PAGE gelsand 
then transferred electrophorectically to a Hybond ECL 
nitrocellulose membrane (Amersham Biosciences, 
USA). Membranes were blocked for 1 hour at room 
temperature with PBS containing 5% non-fat dry milk 
and probed with appropriate primary antibodies O/N 
at 4°C with shaking. Membranes were washed in PBS 
containing 0.1% Tween 20 (PBS/T) and incubated with 
either donkey anti-goat (Santa Cruz Biotechnology, CA, 
USA), goat anti-mouse or goat anti-rabbit IgG 
peroxidase-conjugated secondary antibodies (1:5000) 
(BioRad, Hercules, CA, USA) in blocking solution at 
room temperature with shaking for 1 hour. Membranes 
were again washed in PBS/T and visualized by 
enhanced chemiluminescence (Pierce, USA).  
2.5 Quantitative real-time PCR (qRT-PCR): 
Total RNA was extracted from cells using the RNeasy 
Plus Mini kit (Qiagen, USA). The quality and 
concentration of RNA was determined by 
spectrophotometry. Only samples exhibiting an 
A260/A280 ratio equal to or greater than 1.8 were 
selected and stored at -80°C for further applications. 
Reverse transcription of RNA was performed according 
to the manufacturer’s instructions using the InProm-
IITM reverse transcription system (Promega, USA). 
Briefly, 1 μg of RNA was combined with 0.5 μg of Oligo 
(dT)15 primer in a 5 µl volume and denatured at 70°C 
for 5 min, chilled on ice and combined with reverse 
transcription reaction mix (1X ImProm-IITM Reaction 
buffer, 3 mM MgCl2, 0.5 mM dNTP mix, 20 units 
RNasin® ribonuclease inhibitor and 1 µl of ImProm-II 
TM reverse transcriptase) to a final volume of 20 µl. 
After a brief annealing at 25°C for 5 min, the reactions 
were incubated at 42°C for 1 hour, followed by 15 min 
incubation at 70°C to inactivate the reverse 
transcriptase prior to PCR. qRT-PCR was conducted in 
96 well sealed plates on an Applied Biosystems 
StepOne Plus thermal cycler using 2x SYBR green 
master mix (Applied Biosystems, Carlsbad, CA, USA), a 
final concentration of 0.3 µM of each primer and 2 µl of 
cDNA in a total volume of 10 µl. PCR cycle parameters 
were: denaturation for 15 min at 95°C, combined 
annealing and extension for 35 cycles at 60°C for 1 min. 
Each DNA sample was quantified in triplicate and a 
negative control without cDNA template was run with 
every assay to assess the overall specificity. Melting 
curve analyses was carried out to ensure product 
specificity. Relative mRNA expression levels were 
normalised to human glucuronidase beta (GUSB) or 
human beta-actin using the 2-ΔΔCt method. The 
Microsoft Excel program was used to calculate the 
standard deviation and statistically significant 
differences between samples using the Student t test. P 
values of <0.05 were considered statistically relevant. 
3. Results: 
3.1 Cisplatin exerts a moderate cytotoxic effect 
against HT-29: 
To investigate the cytotoxic effect of cisplatin on 
colorectal cancer cells, the HT-29 cells were treated 
with a range of cisplatin (0 to 100 µM) for 48 hours and 
the MTT assay was used to determine cell viability. The 
concentration that inhibits cell growth by 50 % (IC50) 
was calculated to be 60.8 µM of cisplatin (Figure 1). 
Importantly, previous studies on other cancer cells 
showed that cisplatin exerts its cytotoxic effect at much 
lower concentrations for example its IC50 on breast 
cancer cells (MCF7) and melanoma cells (ME1402) was 
about 10 µM (Aliwaini et al., 2015; Aliwaini, Swarts, 
Blanckenberg, Mapolie, & Prince, 2013). These results 
indicate that the colorectal cell line HT-29 is slightly 
resistant to cisplatin treatment.  
 
 
Figure 1   Cisplatin induces a moderate cytotoxic effect on 
colorectal cancer cells 
 
HT-29 cells were plated in 96-well plates and after 48 
hours the cells were treated with increasing 
concentrations of cisplatin (0-100 μM). Cell viability 
was assessed by the methylthiazoltetrazolium (MTT) 
assay after 48 hours of treatment. The graphs represent 
the mean percentage ± SEM of surviving treated cells 
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relative to control cells of at least three independent 
experiments performed in quadruplicate.  
3.2 Cisplatin up-regulates TBX3 in HT-29: 
The transcription factor TBX3 is up-regulated in a 
group of cancers including breast and colorectal 
cancers (Hoek et al., 2004; Shan et al., 2015; Wu et al., 
2001) and knocking down TBX3 was shown to be a 
useful strategy to enhance chemotherapeutic 
cytotoxicity. Based on the above reports we 
hypothesized that in response to chemotherapeutic 
agents TBX3 levels may be up-regulated resulting in 
cancer cells being less sensitive to these anti-cancer 
treatments. To explore this possibility the effect of 
cisplatin on TBX3 levels was firstly determined. Briefly, 
HT-29 cells were treated with 0.50 µM cisplatin 0.0, 6, 
12, 24 and 48 hours and total protein harvested and 
subjected to western blotting with an antibody to TBX3. 
The results obtained revealed that in response to 
cisplatin treatment TBX3 levels increased in a time-
dependent manner in HT-29 cells (Figure 2-a). To 
investigate whether cisplatin up-regulates TBX3 
transcriptionally or post-transcriptionally, HT-29 cells 
were treated with 50 µM cisplatinfor 6 hours and TBX3 
expression was measured by quantitative real time PCR 
(qRT–PCR) analysis. The results show that cisplatin 
increased mRNA TBX3 level which suggests that 
cisplatin may up-regulate TBX3 transcriptionally 
(Figure 2-b).  
 
 
Figure 2   Cisplatin treatment up-regulates TBX3 protein 
levels 
 
(a) Cisplatin treatment increases TBX3 levels in HT-29 
cells. Protein extract from Ht-29 cells treated with 
vehicle or 50 µM cisplatin for 24 and 48 hours were 
analyzed by SDS-PAGE (8%) and western blotting using 
an antibody to TBX3. p38 was used as a loading control. 
(b) Cisplatin up-regulates TBX3 at a transcriptional 
level, cells were pre-treated with vehicle or 50 µM 
cisplatin and relative TBX3 mRNA levels were 
quantitated using qRT-PCR and normalized to human 
GUSB. Results represent the average of biological 
replicates. Error bars = ±SEM.  
3.3 Knocking down TBX3 enhanced cisplatin 
induced cytotoxicity: 
To investigate the potential role of TBX3 depletion in 
cisplatin-induced cytotoxicity, HT-29 cells were 
transiently transfected with non-silencing siRNA 
(sictrl) or TBX3-specific siRNA (si-TBX3). Transfected 
cells were treated with a range of cisplatin doses (0 to 
100 µM) for 48 hours and the MTT assay was used to 
determine cell viability. Figure 3-b confirms that the 
HT-29 siTBX3 cells used in this experiment did indeed 
have lower levels of TBX3 than the sictrl cells and 
Figure 3-A shows that the siTBX3 cells were more 
sensitive to cisplatin than the sictrl cells. While 50 µM 
of cisplatin killed about 40% of sictrl cells, the same 
concentrations killed 60% of siTBX3 cells. These results 
indicate that knocking down TBX3 might enhance the 
cytotoxic effect of cisplatin in HT-29 cells. 
 
 
Figure 3   Knocking down TBX3 in HT-29 cells enhances 
cisplatin cytotoxic effect 
 
(a) HT-29 siTBX3 cells are more sensitive to cisplatin 
than HT-29 sictrl cells. Cells were plated in 96-well 
plates and cell viability was assessed by the 
methylthiazol tetrazolium (MTT) assay over 24 hours 
of cisplatin treatment. The graph represents the mean 
percentage ± SEM of untreated cells of at least three 
independent experiments performed in quadruplicate. 
A Microsoft Excel student’s t test was performed to 
calculate statistical significance (*p<0.05). (b) Western 
blot of protein from HT-29 sictrl and HT-29 shiBX3 
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cells shows successful TBX3 knockdown in HT-29 
sitBX3 cells.  
4. Discussion: 
The highly homologous TBX3 protein, a member of T-
box family, has been implicated in the progression of a 
number of cancers including a subset of colorectal 
cancers (Hoek et al., 2004; Hoogaars et al., 2008; Peres 
et al., 2010; Shan et al., 2015; Vance, Carreira, Brosch, & 
Goding, 2005). Tbx3 overexpression has been shown to 
be sufficient to immortalize mouse embryonic 
fibroblasts in a process involving the repression of the 
cell cycle regulator p19ARF (Brummelkamp, Kortlever, et 
al., 2002; Brummelkamp, Bernards, & Agami, 2002). 
Two studies later showed that TBX3 interacts with 
histone deacetylases to repress p14ARF, the human 
homolog of p19ARF, in human breast cancer cells where 
it is overexpressed (Fan, Huang, Chen, Gray, & Huang, 
2004; Yarosh et al., 2008). The current study shows 
that knocking down TBX3 led to the sensitisation of the 
HT-29 colorectal cancer cells to cisplatin. In particular, 
depleting TBX3 in Ht-29 cells resulted in an increase in 
cell death. This is in line with the results from a 
previous study which showed that TBX3 is 
overexpressed in a subset of drug resistant 
hepatoblastomas and that its inhibition enhanced 
doxorubicin-induced apoptosis (C-A Renard et al., 
2007). Furthermore, Tbx3 was shown to suppress 
apoptosis by preventing the induction of p53 and its 
target p19ARF in mouse embryo fibroblasts 
overexpressing Myc and Ras (Carlson, Ota, Song, Chen, 
& Hurlin, 2002). In light of these observations, the 
current study showed that TBX3 may be inhibiting the 
cell death in response to cisplatin and might be a cause 
of drug resistance. Importantly, the data provide 
compelling evidence in support of targeting TBX3 in 
combination with cisplatin as a viable option for 
treatment of TBX3-driven colorectal cancer. 
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 القولون سرطان عالج في TBX3 النسخ عامل دور
 األمراض في العوامل هذه دور لىإ السابقة الدراسات شارتأ وكذلك وتطورها األجنة لنمو مهمة TBOX النسخ عوامل تعتبر
 السرطانات من أنواع عدة في مرتفع بشكل يوجد TBX3 النسخ عامل فإن الخصوص سبيل وعلى. السرطان مرض وخاصة
 العامل هذا دور حول مطروحة التساؤالت من العديد فالتزال ذلك من الرغم وعلى. والبروستاتا والقولون الثدي سرطان منها
 سرطان عالج في ما دورا TBX3 العامل هذا لعب امكانية حول أولية مؤشرات تضع الحالية الدراسة. السرطانات عالج في
 .للعالجات السرطان مقاومة بزيادة يؤثر البروتين هذا ان األرجح أن اال الدور هذا في الوضوح عدم من الرغم على. القولون
 كلمات مفتاحية:
TBX3 نسخ عامل، 
 ،القولون سرطان
 .سيسبالتين
